APMD
Apnimed, Inc.$15.28
☾After Hours 0.00 (0.00%)Nov 4, 7:59 PM ET
At close $15.28 · +0.22 (+1.43%)
About APMD
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Cylvex Score
Score currently unavailable
Multi-factor score. Not a buy/sell signal.
Score history
CalibratingScore history appears after more daily scores
What goes into the score
6 axes · equal weightAnalystWall Street consensus & target distance
GrowthEarnings growth trajectory
ProfitabilityROE, margins, cash generation
ValuationPE, PEG, price-to-book ratios
TechnicalsPrice momentum & 52-week position
RiskBeta, volatility, leverage
The Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.